02 September 2021
Visiongain has published a new report entitled the Fill-Finish Manufacturing Market Report 2021-2031: Forecasts by System Type (Integrated Systems, Standalone Systems), by Machine Type (Automated Machines, Semi-Automated, Manual Machines), by Consumables (Pre-filled Syringes, Pre-filled Vials, Pre-filled Cartridges, Other), by End-user (Contract Manufacturing Organizations, Pharmaceutical Companies, Biopharmaceutical Companies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.
The global fill finish manufacturing market was valued at US$xx million in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031. Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference. Automation also decreases the number of people required to execute a process, resulting in cheaper costs and better quality consistency. Automation allows for continuous processing, which allows for more product to be produced in the same amount of time as human manufacturing. Automation, on the other hand, has the disadvantage of being a set process that lacks the flexibility inherent in human operation, especially if an unforeseen incident happens.
How has COVID-19 had a significant negative impact on the Fill Finish Manufacturing Market?
In December 2019 in Wuhan, China was discovered and identified the novel coronavirus disease (COVID-19). On 11 March the outbreak of COVID-19 was identified by the global health organization as a worldwide pandemic (WHO). COVID-19 swiftly spread over the globe in the months ahead and by April 23, 2020 affected almost 2,5 million people. The pandemic COVID-19 affected the global economy and also the pharmaceutical business. The short-term effects of COVID-19 on the health market can be viewed as change in demand, supply scarce, panic purchasing and stocking, regulatory changes, and the transition from communications to distant interactions through the processes of technology and research and development (R&D). COVID-19 is considered to be a century of pharmaceutical business opportunities, increasing demand for prescription medicinal products, vaccinations, and medical devices. This can be considered as one of COVID-19's major short-term effects
How this Report Will Benefit you?
Visiongain’s 430+ page report provides 292 tables and 286 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global fill finish manufacturing market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Fill Finish Manufacturing. Get the financial analysis of the overall market and different segments including system type, machine type, consumable, end-user and capture higher market share. We believe that high opportunity remains in this fast-growing fill finish manufacturing market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the current market drivers?
Growing Demand for Fill-Finish Services
Because of the technical hurdles and specific knowledge involved with aseptic fill-finish operations, pharmaceutical and biopharmaceutical firms are increasingly turning to contract development and manufacturing operations (CDMOs) to handle this critical stage of production. Many businesses lack appropriate fill-finish operations for sterile goods, but even those that do utilise CDMOs as a backup source or transfer from in-house operations to an outsourced partner for commercial manufacture during the early phases of development.
Innovations Drive Changes in Fill-Finish Operations
This dynamic outsourcing industry is driven by innovations in digitization, integrated IT, automation, and environmental conditioning systems. Fill-finish operations with flexible capabilities are becoming more important as the pharmaceutical business shifts away from blockbuster medications and toward specialised, focused therapies for limited patient groups. These aseptic small-batch goods not only present novel sterilisation, handling, and filling problems, but they also necessitate speedier time to market. Advances in cleanroom technology, such as isolators and controlled access barrier systems, have aided the shift to flexible and multi-product fill-finish processes (RABS).
Where are the market opportunities?
Increasing Investment and Flexibility for Effective Manufacturing
Adopting new development techniques, on the other hand, brings with it a new set of problems, which is why collaborating with an industry expert in fill/finish is critical to attaining and ensuring success. Emergent BioSolutions has invested $50 million in expanding its Baltimore Camden plant to satisfy market demands by upgrading fill/finish technology. This, believe, is a required expenditure to fulfil demand.
The Usage of Prefilled Syringe Has Risen Because Of The Disadvantages In The Traditional Process
Because of the drawbacks of the conventional technique, the use of prefilled syringes has increased. Prefilled syringes have several advantages over standard vial packing, including simplicity of use. Prefilled syringes obviate the need for the steps that must be completed before using a medication from a vial. Additionally, because prefilled syringes contain the correct amount, it helps to avoid dosing mistakes.
The major players operating in the fill finish manufacturing market are Becton, Dickinson and Company (BD), Nipro Company, Stevanato Group SpA, West Pharmaceutical Services, Bausch + Ströbel, Gerresheimer AG, Vanrx Pharma systems Inc., Groninger& Co. GmbH, Syntegon Technology, Optima Packaging Group GMBH. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global biologics market was valued at US$382.85 billion in 2022 and is projected to grow at a CAGR of 8.82% during the forecast period 2022-2032.
04 July 2022
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.